Stemline Therapeutics
New York
About Stemline Therapeutics
Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company and a leading developer of novel oncology compounds directed to cancer stem cell targets. Stemline’s lead compound, SL-401, targets the interleukin-3 receptor present on multiple hematological cancers including leukemia blasts and leukemia cancer stem cells. SL-401 has demonstrated single agent anti-tumor activity at tolerable doses in a multi-center Phase I human trial. Behind its lead, Stemline is developing a broad portfolio of compounds directed at this and other high value cancer stem cell targets of a variety of hematological and solid cancers. In addition, Stemline has built a robust discovery platform called “StemScreen®“ which the Company has utilized to identify multiple compounds that target and impair cancer stem cells. Stemline also possesses a comprehensive intellectual property portfolio that includes the earliest filings in the cancer stem cell field covering cancer stem cell-directed therapeutics, diagnostics, and drug screening.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $100K – $500K
- Total funding: $195.1M
- Funding stage: M&A
- Last round: Post-IPO Equity (Aug 2019)
- Ticker: nasdaq:STML
- Website: stemline.com
- Phone: +1 646-502-2311
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Oncology
Social Profiles
Canonical: https://fsome.com/organization/stemline-therapeutics-120978 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.